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Endometrial cancer occurs most commonly in postmenopausal
women and is therefore coincidentally associated with elevated
plasma LH and FSH levels (Nagamani et al, 1993). LH and FSH
secretion is partly controlled by hypothalamic gonadotrophin
releasing hormone (GnRH) and it is notable that recurrent endo-
metrial cancer can be treated with GnRH analogues (Gallagher et al,
1991). However, the exact mechanism by which these analogues
exert their clinical effect on endometrial cancer cell growth is not
fully understood. The in vivo physiological response to GnRH
administration is an initial rise followed by suppression of LH and
FSH secretion (Dowsett et al, 1988). Emons et al (1993) found two
types of GnRH binding sites in the HEC-1A and Ishikawa endomet-
rial cancer cell lines; specific high affinity GnRH receptors were
also found in the DU-145 prostate tumours (Lamharzi et al, 1998).
However, we found no functional GnRH receptor in normal or
malignant endometrium and no direct growth modulating effect in
vitro on endometrial cancer cells (Chatzaki et al, 1996). 
In this study we explore the hypothesis that the antitumour
activity of GnRH is an indirect consequence of reducing circulat-
ing LH and FSH levels. We describe the growth response of
endometrial cancer cells to administration of LH and FSH; the
second messenger response and the expression of LH and FSH
receptors by these cells. 
MATERIALS AND METHODS 
Cell lines 
The human endometrial adenocarcinoma cell line Ishikawa
(Nishida et al, 1985) was a gift from Dr J White (Department 
of Reproductive Physiology, Hammersmith Hospital, London,
UK) and the human endometrial papillary adenocarcinoma cell
line HEC-1A was obtained from the American Type Culture
Collection (Bethesda, MD). The human embryonic kidney cell
lines 293L and 293F derived from 293 cells after stable transfec-
tion with LH and FSH receptor cDNA respectively were donated
by Dr D Segaloff (University of Iowa College of Medicine, Iowa,
USA). 
LH and FSH 
Pituitary-derived LH and FSH were obtained from Sigma (Dorset,
UK) and recombinant human LH and FSH were obtained from 
Dr M Page (Serono). 
Growth experiments 
293, 293L and 293F cells were grown in phenol-red free DMEM
media (Sigma-Aldrich Company Ltd, Dorset, UK) supplemented
with 5% heat-inactivated newborn calf serum (NCS), gentamycin, 
10 mM HEPES, 2 mM glutamine plus antibiotic/antimycotic solu-
tion (Sigma, Dorset, UK). Ishikawa cells were grown in phenol-
red free DMEM nutrient mixture F-12 Ham media (Sigma, Dorset,
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Summary Gonadotrophin releasing hormone analogues (GnRHa) have been used to treat recurrent endometrial cancer. However, the mode
of action is uncertain. Our previous studies showed no direct effect of GnRHa on endometrial cancer cell growth in vitro. We have now
examined the effect of luteinizing hormone (LH) and follicle stimulating hormone (FSH) on endometrial cancer cell growth. The aim was to
determine whether suppression of pituitary LH and FSH by GnRHa could explain the tumour regression seen in up to 44% of patients treated
with this drug. We show that recombinant human LH and FSH (rhLH and rhFSH) produce a concentration dependent stimulation of the
endometrial cancer cell line HEC-1A, in serum-free medium (maximum increase of 62 and 50% respectively relative to untreated controls).
This increase is equivalent to that obtained by addition of 10% newborn calf serum. Growth of the Ishikawa cell line in culture increases in the
presence of rhLH (maximum increase of 67%) but not with rhFSH. Using RT-PCR, we show that the Ishikawa cell line intermittently expresses
receptor mRNA of LH but not of FSH; there is no expression of either mRNA by HEC-1A. Classically, both LH and FSH act via cAMP linked
membrane receptors. However, neither rhLH nor rhFSH elicit cAMP production in either of our endometrial cancer cell lines. Thus, although
a growth response to LH and FSH can be shown, and some cells express the LH receptor, stimulation appears to be via a pathway separate
from that of the classical gonadotrophin receptor. © 2000 Cancer Research Campaign http://www.bjcancer.com
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UK) supplemented with 10% NCS, glutamine plus antibiotic/
antimycotic solution (Sigma, Dorset, UK). The HEC-1A cells
were grown in phenol-red free RPMI-1640 media (Sigma, Dorset,
UK) supplemented with 10% NCS plus antibiotic/antimycotic
solution (Sigma, Dorset, UK). All the cells were grown in 75 cm2
flasks in a humidified atmosphere of 5% CO2 at 37˚C. 
For the growth experiments, cells were plated in 24-well
microtitre plates with serum free media containing 0.1% bovine
serum albumin (104 cells well–1). After a 24-hour settling period,
individual wells were treated with varying concentrations of pitu-
itary derived or recombinant human LH and FSH. The cells were
incubated for 6 days with a medium change every 2 days. The
medium was then removed and the cells were lysed in 1 × Stand-
ard Saline Citrate/0.06% Sodium Dodecyl Sulphate overnight at
–20˚C. DNA content was quantified by the method of Labarca 
and Paigen (1980). 
Cyclic AMP competitive binding assay 
Total cAMP levels were measured after cell incubation for 15 min
with increasing concentrations of LH and FSH (300–10 000 U l–1)
and forskolin (10 µ M) in the presence of 0.25 mM 3-isobutyl-1-
methylxanthine (Sigma, Dorset, UK). The cells were lysed by
boiling, and the cell lysates were assayed for cAMP using a
competitive binding assay. Briefly, this assay relies upon competi-
tion between [3H] labelled cAMP (Amersham, Buckinghamshire,
UK) and unlabelled cAMP in the sample for a crude cAMP
binding protein prepared from bovine adrenal glands (Brown et al,
1971; Farndale et al, 1992). After incubation, free [3H] cAMP is
adsorbed onto charcoal and removed by centrifugation. Bound
[3H] cAMP remains in the supernatant and is measured by liquid
scintillation counting. The protein content of cells was quantified
using the Folin-Lowry method (Lowry et al, 1951) in order to 
standardize the cAMP responses. 
Extraction of messenger RNA 
Messenger RNA was extracted using a standard isolation kit
(Sigma, Dorset, UK). The cells were thawed, removed from
medium, washed in sterile PBS, then lysed, homogenized and
incubated at 45˚C before precipitation of the DNA with 5M
NaCl(aq). The DNA was sheared and oligo (dT) cellulose was
added to bind the mRNA. The oligo (dT) cellulose was then
washed several times in binding buffer and low salt wash 
buffer before release of mRNA from the oligo (dT) cellulose using
elution buffer. The final product was approximately, 0.05 ml of a
solution containing 0.67–5.1 g L–1 mRNA. This was stored at 
–70˚C. 
Reverse transcription-polymerase chain reaction 
(RT-PCR) 
Messenger RNA (3–25.5 µ g) was reverse transcribed using the
oligo (dT) primer and murine leukaemia virus reverse transcript-
ase (MoMLV). Transcription was carried out in a volume of 30 µ l
containing 1× reverse transcription buffer, 0.075 mM dNTPs, 
10 ng µ l–1 oligo (dT)15 primer; 2 mM dithiothreitol (DTT) and 
4 U µ l–1 MoMLV-reverse transcriptase. The reaction mixture was
incubated at 42˚C for 1 h in a Techne thermal cycler. 
5 µ l of this cDNA preparation was subjected to 35 cycles of
amplification using a Techne thermal cycler. The polymerase
chain reactions (PCRs) were carried out in a 25 µ l reaction mixture
with a PCR bead (Amersham, Buckinghamshire, UK) containing
10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 200 µ M
dNTPs and 1.5 U of Taq DNA polymerase and 400 mM of each
primer. A PCR was set up for the LH/FSH receptors using
oligonucleotide primers that span intronic sequences specific for
each receptor (Table 1). 
After initial denaturation for 2 min at 94˚C, 35 cycles of ampli-
fication were performed with 1 min denaturation at 94˚C, 50s
annealing temperature and 50 s extension at 73˚C. The last cycle
had an elongation time of 10 min at 73˚C. 
Gel electrophoresis 
An aliquot of the PCR reaction mixture was examined on a 2%
agarose gel, stained with ethidium bromide and photographed
under UV light. 
Actin controls 
In order to check the integrity of the reverse transcriptase reaction
the expression of the house keeping gene actin was used as a
control. A forward (CAG CCA TGT ACG TTG CTA TCC AGG)
and reverse primer (TTG CGG ATG TCC ACG TCA CAC TTC)
spanning intron 4 of the human cytoplasmic beta-actin gene
(Nakajima-Iijima et al, 1985) were used in a PCR reaction as
described above but with an annealing temperature of 66˚C.
Genomic DNA contamination would yield a product of 579 bp and
cDNA a product of 483 bp. 
RESULTS 
Stimulation of cell growth by LH and FSH 
HEC-1A cell growth was stimulated by pituitary-derived LH and
FSH by 75 and 77% respectively relative to untreated controls.
Table 1 Primers used in PCR amplification for the LH and FSH receptors. The site of hybridization
and annealing temperatures are shown 
Primer Location Nucleotide sequence Annealing temperature 
hLH-R 5′ 676/698 5′ -CCTGGATATTTCTTCCACCAAA-3′ 55˚C 
hLH-R 3′ 1270/1291 5′ -TGGCATGGTTATAGTACTGGC-3′ 55˚C 
hFSH-R 5′ 264/285 5′ -GGTGCATTTTCAGGATTTGGGG-3′ 62˚C 
hFSH-R 3′ 527/552 5′ -TTGTGTGGATGTTTATGTTATCTTG-3′ 62˚C HEC-1A cell growth also increased in a concentration dependent
manner when exposed to rhLH (100–300 U L–1) and rhFSH
(300–1000 U L–1) with maximum increases of 62% and 50%,
respectively. This is comparable to the effect of 10% NCS, in
the presence of which cell numbers were stimulated relative to
untreated controls by 76% and 68% (Figure 1). 
The growth of Ishikawa cells was stimulated by pituitary-
derived LH by 50%. Ishikawa cells also increased in culture in a
dose-dependent manner when exposed to rhLH with a maximum
increase of 67% at 1000 U L–1. This is comparable to the effect of
10% NCS which stimulated an 85% increase (Figure 2). However,
no growth effect was seen with rhFSH. 
Second messenger activity 
Control cell lines 293L and 293F show a rise in cAMP production
following stimulation with varying concentrations of LH and FSH
respectively (Figure 3). By contrast, cAMP production did not
increase in response to LH and FSH in either endometrial cancer
cell line. All cell lines showed a dramatic increase in cytoplasmic
cAMP (> 10000 U L–1) when exposed to 10 µ M forskolin (results
not shown). 
Expression of hLH receptor 
The positive control yielded the expected size band (616 bp). The
hLH receptor was expressed by the endometrial cancer cell line
Ishikawa but not by HEC-1A (Figure 4). However, this band was
not consistently seen in repeat experiments. 
Expression of the hFSH receptor 
The positive control yielded the expected size band (289 bp). 
The hFSH receptor was not expressed by HEC-1A or Ishikawa 
(Figure 5). 
DISCUSSION 
Endometrial cancer responds to treatment with GnRHa. Some
28% of postmenopausal women with recurrent endometrial cancer
showed clinical improvement with monthly depot injections of
GnRH analogues; long-term survival was 44% (Jeyarajah et al,
1996). The mechanism of this action is not understood. It has been
suggested that GnRH analogues have a direct antitumour effect on
endometrial cancer cells but there is no direct effect of GnRH
analogues on endometrial cancer cell growth in vitro (Chatzaki 
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Figure 1 Effect of varying concentrations of rhLH (A) and rhFSH (B) on the
growth of endometrial cancer cell line HEC-1A in phenol red-free media over
6 days of treatment. Cells grown in 10% NCS were used as positive controls.
All results are expressed as a percentage of non-treated controls. Each
determination was performed in 15 replicates; bars represent standard error
of the mean. The asterisk shows statistical significance (P < 0.05) 
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Figure 2 Effect of varying concentrations of rhLH (A) and rhFSH (B) on the
growth of endometrial cancer cell line Ishikawa in phenol red-free media over
6 days of treatment. Cells grown in 10% NCS were used as positive controls.
All results are expressed as a percentage of non-treated controls. Each
determination was performed in 15 replicates, bars represent Standard Error.
The asterisk shows statistical significance (P < 0.05) et al, 1996). Imai et al (1994) described GnRH receptor mRNA
expression in the human endometrium but this could not be
confirmed by other studies on normal or malignant endometrium
(Chatzaki et al, 1996). 
GnRH analogues are widely used in cancer treatment: for
example, they have been administered to postmenopausal women
with locally advanced or metastatic breast cancer. The most
notable endocrine change found in postmenopausal women treated
with such analogues is a reduction in plasma LH and FSH concen-
trations. Dowsett et al (1988) reported that the mean serum LH
level fell progressively to 8.2% of the pre-treatment value after 4
weeks of treatment and thereafter ranged between 5.5–6.2% of the
pre-treatment level; the mean serum FSH level fell to 8.6% of the
pre-treatment value after 3 weeks and thereafter ranged between
7.5–9.5% of the pre-treatment value. Similarly, in endometrial
cancer patients treated with a GnRH analogue, gonadotrophin
levels were suppressed within the first 2 months of use (Jeyarajah
et al, 1996). 
Given that there is no functional GnRH receptor in normal or
malignant endometrium (Chatzaki et al, 1996), it was reasonable
to assume that endometrial cancer may be associated with
gonadotrophin receptor expression. Growth may be retarded by
the profound and sustained suppression of the high postmeno-
pausal gonadotrophin levels which occurs with GnRH analogue
treatment. In this study, we show that growth of HEC-1A was
stimulated by the addition of recombinant LH and to a lesser
extent by FSH (Figure 1). Ishikawa cells also increased in culture
in a dose-dependent manner when exposed to rhLH but not 
rhFSH (Figure 2). Simon et al (1983) have demonstrated that LH
and FSH stimulated the growth of cell lines derived from malig-
nant epithelial tumours and thus this study is in agreement.
However, they went on to demonstrate gonadotrophin receptor
mRNA expression by benign and malignant human epithelial
lesions. However, at best we were able to demonstrate an intermittent
expression of LH receptor but not FSH receptor mRNA (Figures 4
and 5). Nevertheless, Lin et al (1994) have also demonstrated LH
receptor mRNA expression by endometrial cancer cell lines. 
Despite this, it is not clear how gonadotrophin receptor activa-
tion can regulate cell growth. LH and FSH normally act via cAMP.
In this study, these hormones did not elicit cAMP production in
HEC-1A or Ishikawa cells (Figure 3) although they did stimulate
cell growth (Figures 1 and 2). Though we were unable to show a
classical cAMP second messenger response to LH and FSH, it is
Glycoprotein hormones and endometrial cancer 1733
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Figure 3 (A) Cyclic AMP production by the gonadotrophin receptor-positive
293 cells and the endometrial cancer cell lines HEC-1A and Ishikawa in
response to varying concentrations of LH (300–10000 U L–1). (B) Cyclic AMP
production by the gonadotrophin receptor-positive 293 cells and the
endometrial cancer cell lines HEC-1A and Ishikawa in response to varying
concentrations of FSH (300–10000 U L–1) 
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Figure 4 PCR amplification of the hLH receptor. The PCR products were
analysed by agarose gel electrophoresis and visualized by ethidium bromide
staining under UV light. M, 100 bp DNA ladder. Lane 1 derived from a PCR
reaction in the absence of DNA. The PCR products from testis cDNA (Lane
2), HEC-1A cDNA (Lane 3) and Ishikawa cDNA (Lane 4) are presented. The
predicted 616 bp band can be seen in the endometrial cancer cDNA for
Ishikawa but not for HEC-1A 
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Figure 5 PCR amplification of the hFSH receptor. The PCR products were
analysed by agarose gel electrophoresis and visualized by ethidium bromide
staining under UV light. M, 100 bp DNA ladder. Lane 1 derived from PCR
reaction in the absence of DNA. The PCR products from testis cDNA 
(Lane 2), HEC-1A cDNA (Lane 3) and Ishikawa cDNA (Lane 4) are
presented. The predicted 289 bp size band cannot be detected in the
endometrial cancer cDNA for HEC-1A or Ishikawa 1734 S Davies et al
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possible that they might act via a different pathway to promote cell
growth in endometrial cancer. Gonadotrophin receptors are also
coupled to the inositol phosphate-protein kinase C (IP-PKC)
pathway (Grudermann et al, 1992). However, gonadotrophin
levels sufficient for IP3 stimulation are observed only during the
pre-ovulatory surges and pregnancy, suggesting that the physio-
logical role, if any, of the IP-PKC pathway in conveying the
biological actions of gonadotrophins to target cells is limited to
these situations (Grudermann et al, 1992). These studies strongly
suggest that high postmenopausal levels of LH and possibly FSH
are stimulating endometrial cancer cell growth but not via the
classical LH receptor-cAMP pathway. 
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